We reviewed gonadal function in 270 patients who underwent bone marrow transplantation (BMT) between 1974 and 1988. Age at transplant ranged from 6 to 54 years (mean 25.6 years). Diagnoses included acute myelogenous leukemia, chronic myelogenous leukemia, aplastic anemia, acute lymphoblastic leukemia, non-Hodgkin lymphoma, Hodgkin's disease and other diagnoses. Effects of patient characteristics on risk of gonadal dysfunction were analyzed by comparing the cumulative probability of developing gonadal dysfunction over time from BMT. Ninety-two percent of the males and 99% of the females developed evidence of gonadal dysfunction. Females were not only more likely to develop elevated gonadotrophin levels than males, but did so earlier after BMT. Odds ratios were calculated to determine potentially important prognostic factors for the development of an elevated gonadotrophin level. Older age at BMT was correlated with an increased risk in the development of elevated gonadotrophin levels. Individuals who received radiation were more likely to develop an elevated FSH level over time than those who had received no preparative radiation treatment. Males were more likely to experience gonadal recovery than females. In those cases that did recover, males tended to recover more quickly after BMT than females. Keywords: gonadal dysfunction; bone marrow transplant; risk; late effects
dal damage in both adults and children, and appears to be dose-related and in some instances reversible in males. [2] [3] [4] Several studies have shown that high-dose chemotherapy and TBI are associated with gonadal dysfunction and failure of gonadal recovery in females. 4, 5 These studies also suggest that recovery of ovarian function, but not recovery of testicular function, is more likely to be seen in those who receive fractionated TBI than in individuals who receive single dose TBI. 3, 4 The objectives of this retrospective review of individuals who had undergone BMT at the University of Minnesota were to determine the percentage of individuals who developed gonadal dysfunction after bone marrow transplantation, the time to the first documented evidence of gonadal dysfunction after BMT, and the factors associated with this gonadal dysfunction. This study also sought to determine the percentage of individuals who achieved gonadal recovery following dysfunction, the timing of this recovery, and the factors associated with recovery.
Patients and methods

Selection of patients
This study was designed as a retrospective cohort study. Eligible cases were defined as all individuals who had undergone a bone marrow transplant at the University of Minnesota Hospital between 1974 and 1988, and who had survived at least 1 year after transplant. Additionally, in order to effectively evaluate pubertal development, individuals were required to have reached the age of 15 at the time of their most recent post-bone marrow transplant evaluation.
Data were obtained from the BMT database at the University of Minnesota on all eligible individuals, which included the unique patient number (UPN), sex, initial diagnosis, date of birth, date of BMT, preparative chemotherapeutic agents and preparative radiation treatment. Documented clinical information was also obtained through a review of medical records, on all clinical evaluations of both gonadotrophin levels and gonadal function after BMT. Clinical evaluations, which included laboratory evaluation of gonadotrophin levels and thyroid function, were assessed at 100 days, 1 year, 2 years and annually after BMT.
Definition of gonadal dysfunction
Gonadal dysfunction in males was defined as a documented elevated level of either follicle stimulating hormone (FSH) or luteinizing hormone (LH), or the use of androgen replacement. Gonadal dysfunction in females was also defined using documented elevated FSH or LH levels, or documented use of oral contraceptives for replacement therapy. Information on birth control pill usage and the reason for usage (hormonal replacement therapy vs contraception) was abstracted on females.
Elevated gonadotrophin levels were defined as FSH levels у25 IU/ml, and LH levels у20 IU/ml, which is the cutoff chosen at the UMHC laboratories. For the purposes of analysis, gonadal recovery was defined in both males and females as a return to normal of gonadotrophin levels, without androgen or oral contraceptive replacement. Sex steroid therapy was not routinely given to determine if ovarian recovery had occurred in females. Semen analysis and testicular volume were not carried out routinely in males.
Statistical analysis
Event analysis was performed, utilizing the Kaplan-Meier product-limit method of estimating cumulative probability. 6 The time variable for this analysis was defined as the number of days from BMT to the first documented event of an elevated gonadotrophin level or hormone replacement. Cases were censored in this analysis either after the last follow-up visit or after 8 years of follow-up. Event analysis was also used to compare the curves of patient characteristics identified as potentially important prognostic factors.
The P values reported were determined using the approximate 2 statistic for the Wilcoxon test. Logistic regression 7 was used to determine the odds of the development of a documented elevated gonadotrophin level for individual prognostic factors and to look at these possible prognostic factors within a multiple logistic regression model. Logistic regression models were also used to identify risk factors which would predict gonadal recovery after gonadal dysfunction.
Patient population
One hundred and sixty-one males (60%) and 109 females (40%) were included in this review ( Of the 270 eligible cases, only 31 individuals received no preparative radiation treatment. For those who received preparative radiation treatment, 41 individuals underwent total lymphoid irradiation (TLI), and 198 received total body irradiation (TBI) either on a single fraction (n = 69), hyperfractionated (twice/day) (n = 126), or superfractionated (three times/day) (n = 3) schedule. Preparative therapy administration involved 750 cGy of total lymphoid irradiation in a single fraction at 26 cGy/min for TLI, 750 cGy of total body irradiation at 26 cGy/min as a single dose for TBI-single dose, 1320 cGy (165 cGy twice daily for 4 days) at 5-10 cGy/min for TBI-hyperfractionated, and 1375 cGy (11 fractions over 4 days) at 10-19 cGy/min for TBI-superfractionated regimens.
Preparative chemotherapy drugs used at BMT for this cohort included cyclophosphamide, busulfan, BCNU, cytosine arabinoside, etoposide and teniposide. Of the eligible cases in this study, 75% received cyclophosphamide alone, 15% received cyclophosphamide with other chemotherapeutic agents, and 10% received other agents, with no cyclophosphamide. Cyclophosphamide was generally administered between two and four times, resulting in a total dosage of 120-200 mg/kg.
Results
Event analysis curves have been drawn to show the cumulative probability of developing an elevated gonadotrophin level after BMT for both males and females in Figure 1 . Event analysis curves were also used to determine potential prognostic factors for both elevated FSH levels and elevated LH levels. Curves for elevated FSH levels only, with 
Gender
When comparing the cumulative probability of the first documented elevated FSH level over time from BMT between gender, both males and females showed a similar sharp rise in the proportion of individuals with elevated FSH levels (Figure 1) . At 1 year, the cumulative probability of a documented elevated FSH level was 69.8% for males, and 73.3% for females. This cumulative probability increased to 85.3% and 94.4%, respectively, by 5 years post-BMT. By the 8th year of follow-up after BMT, the cumulative probability had risen to 90.0% for males and 97.2% for females. When comparing LH levels, however, males showed a significantly slower rise over time to the first documented elevated LH level than females (P = 0.03). At 1 year, the cumulative probability of a documented elevated LH level was 61.8% for males, and 73.0% for the females, with this increasing to 84.4% and 95.4%, respectively, at 5 years. After 8 years of follow-up from BMT, the cumulative probability for a documented elevated LH levels was 91.9% for males and 98.5% for females.
Age at BMT
Age at BMT categories were chosen as follows: prepubertal (0-10), pubertal (11-15), post-pubertal (16-25), older adult (у26). When age at BMT was evaluated as a potential prognostic factor, comparisons of the cumulative probability showed a statistically significant difference in the number of days to the development of an elevated FSH level by age at BMT (overall test of difference between age categories; P value Ͻ0.01), with younger age at BMT associated with a delayed time to the first documented elevated FSH level (Figure 2) . At 1 year after BMT, the cumulative probability of developing an elevated FSH level was 23.5% for those 10 years of age or younger at BMT, 52.4% for those 11-15 years, 69.2% for those 16-25 years, and 87.4% for individuals who were 26 years or older at BMT. After 5 years of follow-up from BMT, a significant difference is still seen, with cumulative probabilities increasing to 47.7, 73.3, 94.4 and 100.0%, respectively, with age at BMT.
Gonadal damage in pre-pubertal children may not be associated with elevated gonadotrophin levels until puberty. Therefore, a delay in the occurrence of elevated gonadotrophin levels may not reflect an absolute protective effect of young age. To assess this difference in age at BMT without the influence of a pubertal effect, gonadotrophin levels in individuals who were 20 years of age or older at their last follow-up visit were compared by age at BMT ( Table 2 ). The proportion of individuals who were abnormal at their last clinical evaluation, increased with age at BMT for both males and females. For males and females combined this did reach statistical significance for FSH (P = 0.04 for trend) and for LH (P = 0.004 for trend).
Diagnosis
An individual's initial diagnosis prior to BMT showed a statistically significant difference in the pattern of the cumulative probability curves to the development of an elevated FSH level (overall test of difference between diagnoses; P value = 0.01) (Figure 3) . At 1 year, the cumulative probability of the development of the first elevated FSH level after BMT was higher for both HD (86.4%) and CML (86.8%) than the diagnoses of ALL (64.7%), AML (61.1%), NHL (59.7%), and aplastic anemia (59.5%). After 5 years, diagnoses of HD (100.0%), CML (100.0%), ALL (91.9%), AML (89.6%) and NHL (87.4%) all had higher cumulative probabilities of developing an elevated FSH level than aplastic anemia (69.2%). When looking at age at BMT within diagnosis, individuals diagnosed with HD and CML are older at BMT (mean age at BMT, 32 and 29 years, respectively), and aplastic anemia and ALL are younger at BMT (21 and 19 years, respectively). When controlling diagnosis groups for age at BMT, the difference between diagnoses was no longer statistically significant. 
Preparative radiation
When comparing the type of preparative radiation treatment received, the cumulative probability curves of developing an elevated FSH level showed a nonsignificant statistical difference (overall test of difference between treatments; P value = 0.06) among these groups (Figure 4) . At 1 year, the cumulative probability of developing an elevated FSH level was lower for no radiation (64.4%) and single dose TBI (53.3%), and was higher for TLI (71.0%) and fractionated TBI (71.7%). After 5 years, cumulative probabilities increased, with individuals who received no radiation lower (74.1%) than those who received single dose TBI (82.1%), TLI (83.1%), and fractionated TBI (98.0%).
Within different preparative radiation treatments, females showed a higher cumulative probability of developing an elevated FSH level than males. This difference was most pronounced for individuals receiving TLI. After 5 years, the cumulative probability of developing an elevated FSH level for those receiving no radiation, TLI, single dose TBI and fractionated TBI was 70.0, 71.9, 76.6 and 96.6%, respectively, for males, and 80.0, 94.1, 85.4 and 100.0%, respectively, for females.
Preparative chemotherapy
No differences were seen in the cumulative probability of developing an elevated FSH level or LH level, when comparing those who had received cyclophosphamide as a preparative chemotherapy agent, to those who had not received cyclophosphamide.
Odds ratio estimates
The odds ratio associated with the development of an elevated gonadotrophin level and prognostic factors of interest were calculated using univariate logistic regression (Table 3) . Results comparable to the event analysis were seen. A statistically significant increase in risk was seen with an increase in the age at BMT for both FSH and LH levels (P value Ͻ0.01). When compared to individuals who underwent a BMT before the age of 11, the odds ratio estimates associated with an elevated FSH level increased from 1.3 for ages 11-15, to 4.4 for ages 16-25, and 5.6 for those over the age of 26 years. When compared to aplastic anemia, only CML showed a statistically significant higher risk of developing an elevated FSH level after BMT (odds ratio = 19.0, P value Ͻ0.01).
Of the preparative radiation used, both TLI and singledose TBI showed a statistically nonsignificant increase in the odds ratio of developing an elevated gonadotrophin level, when compared to the no radiation group. Hyperfractionated TBI was shown to be nine times more likely than those with no radiation, to be associated with an elevated FSH level (P value Ͻ0.01).
A stepwise logistic regression model was used to determine which prognostic factors were statistically associated with the development of an elevated gonadotrophin level. Factors of interest included sex, age at BMT, diagnosis, preparative radiation treatment and preparative chemotherapy. Results from this analysis showed that the develop- * P value Ͻ0.05, ** P value Ͻ0.01. ment of an elevated FSH level was associated with fractionated TBI preparative radiation, CML diagnosis, and female sex (P value Ͻ0.05). Results also showed that the development of elevated LH levels after BMT, was associated with both older age at BMT and female sex (P value Ͻ0.05).
Gonadal recovery
Of the males who had developed an elevated gonadotrophin level, 13 (10.5%) had a return to normal of FSH levels, and 24 (21.1%) of LH levels. When looking at potential prognosis factors for gonadal recovery in males, the type of radiation treatment was significantly associated with gonadal recovery after gonadal dysfunction. Of the males that recovered, all had received radiation. Males who did not have a return to normal of gonadotrophin levels were more likely to have received TBI (either single or fractionated) than TLI (for FSH, odds ratio = 5.8, 95% CI = 1.6, 21.0), (for LH, OR = 4.9, 95% CI = 1.6-15.0). Age at BMT, diagnosis and cyclophosphamide chemotherapy were not associated with recovery of gonadotrophin levels in males.
Of the females in this study, 66.3% had documented use of oral contraceptives. Of those women who had not received oral contraceptives, three (10.3%) had a return to normal of gonadotrophin levels. Age at BMT for these individuals was: 13 years (diagnosed with AA), 29 years (diagnosed with NHL), and 37 years (diagnosed with CML). No association was found between potential risk factors and gonodal recovery in females.
Discussion
As BMT becomes a more common therapeutic option for both malignant and nonmalignant disease in children and adults, future efforts to decrease the long-term sequelae will assume increasing importance. The definition of patient and treatment characteristics associated with these long-term sequelae is the first step in reducing the long-term morbidity associated with this therapeutic option.
Several studies have documented endocrine problems in children and adults after bone marrow transplantation. [2] [3] [4] [5] [8] [9] [10] [11] [12] [13] Our experience is similar in that the overwhelming majority of patients experience some degree of gonadal dysfunction following BMT. In our analysis, older age at BMT was a consistent and important risk factor for developing gonadal dysfunction over time. Because examination of timing from BMT to first abnormality is influenced by age (younger patients who may ultimately become abnormal may not manifest this until puberty), we evaluated the likelihood of ever developing dysfunction. There was a statistically significant trend toward an increasing likelihood of eventual dysfunction with increasing age for elevated FSH and LH. In addition to illustrating the protective effect of young age, this also points out the need for continued follow-up of patients transplanted during childhood for evidence of ultimate gonadal damage.
Previous studies have shown that the germinal epithelium of the testis is more vulnerable to the effects of cyclophosphamide and irradiation, particularly in post-pubertal males, whereas Leydig cells retain normal function when cyclophosphamide is given alone, and when radiation dosage to the testis is less than 20 Gy. 2, 5 Since over 86% of the male population in this study received cyclophosphamide, it is difficult to determine its contribution to the effect seen in our population. Evidence from our study suggests that germ cell function is sensitive to irradiation, indicated by elevated FSH levels (90% after 8 years of followup) and that Leydig cell function appears to be also, indicated by elevated LH levels (92% after 8 years of followup). Our data also support the theory that fractionated TBI is more deleterious to spermatogenesis than single fraction TBI or TLI (cumulative probability of developing an elevated FSH level was 96.6 vs 76.6% and 71.9%, respectively).
In females who undergo BMT, normal ovarian function is generally retained with cyclophosphamide alone, 4 but function is at an increased risk with high doses of radiation, whether fractionated or not. 4, 5 In this study, similar elevated FSH levels were seen with each preparative radiation treatment, but were lower for those who received only chemotherapy as preparative treatment. This supports the theory that ovarian failure is due not only to the dose per fraction, but also to the total dose received.
Previous studies have also shown that the timing of, and the potential for, recovery from this gonadal dysfunction, may be modified by both treatment and patient characteristics. 3 Although recovery of gonadal function (as indicated in this study, by normalization of gonadotrophins without exogenous androgens or estrogens) was uncommon, 13 males who had elevated FSH levels that returned to normal, five (38.5%) received cyclophosphamide and TLI, and four (30.8%) received hyperfractionated TBI, compared to 11.3% and 52.6%, respectively, who received similar preparative treatment overall in this study. Despite these small numbers, this suggests that radiation schedule impacts upon the likelihood of gonadal recovery, as well as on the likelihood of the development of dysfunction. In females, only three women recovered gonadal function without oral contraceptive use: the first, aged 29 at BMT received single dose TBI, the second, aged 13 at BMT received cyclophosphamide and TLI, and the third, aged 37 at BMT, received cyclophosphamide and hyperfractionated TBI. Oral contraceptive replacement was administered in all other cases where gonadal function recovered.
There are limitations to this type of retrospective cohort study. Because all individuals received BMT in one institution, there is an intrinsic association between age at BMT, diagnosis, and preparative radiation and chemotherapy. For example, cases diagnosed with AA, AML and ALL were found in all age categories, whereas CML, HD and NHL cases were all over the age of 12 at the time of BMT. When looking at treatment, no HD case received radiation treatment in the preparative regimen, most individuals diagnosed with AA received TLI, and all CML cases received fractionated TBI. Therefore, care must be taken when comparing these patient characteristics. Since age at BMT, diagnosis and radiation treatment are related to each other, this overlap of information may cause difficulty when attempting to ascertain exactly which characteristic is the most statistically significant.
Previous literature has suggested that alkylating agents in males and abdominal radiation in both boys and girls, may cause primary germ cell dysfunction. Also, testicular radiation has been shown to cause permanent Leydig cell damage in boys, and ovarian radiation causes ovarian failure in girls. Since most individuals in this study were referred to this institution for transplant, another limitation to a cohort study as large as this, is that it was not possible to obtain information on other chemotherapeutic agents used to induce first remission, which may influence the likelihood of gonadal damage. This cohort, however, is representative of patients who undergo BMT. Therefore, when evaluating individual cases for possible gonadal dysfunction, it will be important to consider possible additive effects from chemotherapy and radiation received prior to BMT as well as that given as a preparative regimen for BMT.
In summary, these data confirm that following BMT a large fraction of individuals, 92% of the males and 99% of the females, will experience gonadal dysfunction. Those individuals who are older at BMT appear more likely to develop elevated gonadotrophin levels, and these elevated levels are seen a shorter time from transplant than those who undergo transplant at a younger age. Females were also more likely to develop elevated gonadotrophin levels than males, also at an earlier time period after BMT. Additionally, males are more likely to experience gonadal recovery than females, and in those cases that do recover, males tend to recover more quickly after BMT than females.
